Aptose Biosciences (APTO – Research Report) received a Buy rating and a $14.00 price target from JonesTrading analyst Soumit Roy today. The company’s shares closed last Monday at $4.36, close to its 52-week low of $3.92.
According to TipRanks.com, Roy is a top 100 analyst with an average return of 75.3% and a 60.4% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Monopar Therapeutics Inc.
Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $10.83.
The company has a one-year high of $9.00 and a one-year low of $3.92. Currently, Aptose Biosciences has an average volume of 1.56M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.